These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9833388)

  • 1. Tamoxifen and peripubertal women.
    Costello SA; Bassford C
    Australas Radiol; 1998 Nov; 42(4):397. PubMed ID: 9833388
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing breast cancer with tamoxifen.
    Health News; 1998 May; 4(6):1, 5. PubMed ID: 9602560
    [No Abstract]   [Full Text] [Related]  

  • 3. Tamoxifen for breast cancer prevention.
    Force RW
    J Fam Pract; 1998 Nov; 47(5):336-7. PubMed ID: 9834765
    [No Abstract]   [Full Text] [Related]  

  • 4. Should we discontinue tamoxifen in a patient with vision-threatening ocular toxicity related to low-dose tamoxifen therapy?
    Tsai DC; Chen SJ; Chiou SH; Lee AF; Lee FL; Hsu WM
    Eye (Lond); 2003 Mar; 17(2):276-8. PubMed ID: 12640432
    [No Abstract]   [Full Text] [Related]  

  • 5. Tamoxifen.
    Nurs Times; 2006 Feb 21-27; 102(8):33. PubMed ID: 16519033
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoprevention of breast cancer for women at high risk.
    Chan K; Morris GJ
    Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should you be taking tamoxifen?
    Johns Hopkins Med Lett Health After 50; 2001 Jun; 13(4):4-5. PubMed ID: 11439691
    [No Abstract]   [Full Text] [Related]  

  • 8. The beneficial effect of the estrogen antagonist tamoxifen on experimental systemic lupus erythematosus.
    Thylan S
    J Rheumatol; 1995 Aug; 22(8):1606-7. PubMed ID: 7473493
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chemoprevention of breast cancer. Impact of a new therapeutic strategy].
    Kattan J; Ghosn M
    J Med Liban; 1999; 47(5):284-5. PubMed ID: 10887527
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract]   [Full Text] [Related]  

  • 11. Tamoxifen in cancer therapy: minireview.
    Novotny L; Rauko P; Vachálková A; Peterson-Biggs M
    Neoplasma; 2000; 47(1):3-7. PubMed ID: 10870680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of breast cancer in high-risk women.
    Kardinal CG; Veith R
    J La State Med Soc; 1999 Apr; 151(4):198-201. PubMed ID: 10234895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SERM--selective estrogen receptor modulators].
    Kønig KB; Eiken PA; Schwarz P
    Ugeskr Laeger; 2001 Apr; 163(15):2129-33. PubMed ID: 11332210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmenopausal HRT--a role for a safe antioestrogen.
    Williams GM
    Int J Clin Pract; 1998; 52(1):5. PubMed ID: 9536558
    [No Abstract]   [Full Text] [Related]  

  • 16. [The effects of tamoxifen on the female genital tract].
    Mourits MJ; van der Zee AG; Willemse PH; Hollema H; de Vries EG
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2315-20. PubMed ID: 14669536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
    Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
    Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
    Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
    Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial carcinoma can develop in patients on tamoxifen therapy.
    Omar SZ; Sivanesaratnam V
    Med J Malaysia; 1999 Jun; 54(2):280-2. PubMed ID: 10972045
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
    J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.